Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K
Nature. 2010 467 (7315): 596-9

PMID: 20823850 · PMCID: PMC2948082 · DOI:10.1038/nature09454

MeSH Terms (21)

Alleles Animals Dogs Extracellular Signal-Regulated MAP Kinases Humans Indoles Macaca fascicularis MAP Kinase Signaling System Melanoma Models, Molecular Mutant Proteins Mutation Neoplasm Metastasis Phosphorylation Positron-Emission Tomography Proto-Oncogene Proteins B-raf Rats Substrate Specificity Sulfonamides Vemurafenib Xenograft Model Antitumor Assays

Connections (2)

This publication is referenced by other Labnodes entities:

Links